Prana moves forward on Alzheimer's treatment
Friday, 05 April, 2002
A treatment for Alzheimer's Disease is one step closer after the successful completion of a Phase II clinical trial by Prana Biotechnology for its drug PBT-1 (Iodochlorhydroxyquin).
The trial was performed on 32 patients. Half of the patients received the drug and half received a placebo, in a randomised double blind study. Full analysis of the results has not been completed.
Earlier studies in transgenic animals were published last year in the journal Neuron.
Prana's Executive Chairman, Geoffrey Kempler, said that as the current study was being prepared for publication, the company could not comment further on the results at this point in time.
Kempler said the company was pleased with the results, "It has given us a vote of confidence to keep moving forward."
Scientists uncover how cancer cells hide from immune system
By targeting the RNA helicase known as DDX6, scientists could enable the immune system to...
Vanillin flavouring in vapes may disrupt embryo development
Vanillin — a common flavouring chemical in e-cigarettes — may disrupt the normal...
Heart valve tissues created from stem cells
The breakthrough should help advance our understanding into how human heart valves develop,...
